Intraclonal genetic diversity in individual patients' cancer cells is predictive of drug resistance and poor outcome. A major challenge of cancer therapeutics is how to thwart the resilience of the evolutionary process. This session will address three key aspects of this topic:

• How we can best measure diversity?
• Does the degree of diversity predict outcome?
• How can we tackle or bypass clonal diversity, therapeutically?